ERBB2 and breast carcinoma: For example, in HER2-overexpressing breast cancer, trastuzumab, an anti-HER2 monoclonal antibody, has drastically improved patient prognosis in adjuvant and neoadjuvant (Buzdar et al, 2005; Piccart-Gebhart et al, 2005; Romond et al, 2005; Untch et al, 2010) setting when combined with chemotherapy.